News

Prevacus Announces the Addition of Key Individuals to its Sports Advisory Board

TALLAHASSEE, Fla., Feb. 22, 2017 (GLOBE NEWSWIRE) — Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders; today announced the addition of Steve Mariucci, Eddie DeBartolo Jr., Matt Hasselbeck and Warren Moon to its sports advisory board. “I am delighted to have the […]

Read More »

Prevacus to Begin Phase 1 Clinical Studies of PRV-002 for the Treatment of Concussion

TALLAHASSEE, Fla., Feb. 09, 2017 (GLOBE NEWSWIRE) — Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion aka mild Traumatic Brain Injury (mTBI) and other neurological disorders; today announced plans to initiate Phase 1 clinical studies of a novel treatment for concussion in humans. The Company expects to initiate its Phase 1 […]

Read More »

Dr. Jake VanLandingham: “It’s Time to Change the Way We Treat Concussions, Not the Game of Football.”

Tallahassee, FL – Dr. Jake VanLandingham, an expert in the field of neuroscience and Founder and President of Prevacus Inc., a Florida-based pharmaceutical company currently developing the first field-deliverable drug to treat concussions, said the new rule issued by the NCAA to protect athletes from concussions reiterates the importance of developing a treatment to the […]

Read More »